Fagron NV (EBR:FAGR)
23.65
-0.20 (-0.84%)
Jul 22, 2026, 10:00 AM CET
Fagron NV Revenue
In the year 2025, Fagron NV had annual revenue of 952.17M EUR with 9.20% growth. Fagron NV had revenue of 476.04M in the half year ending December 31, 2025, with 21.62% growth.
Revenue
952.17M
Revenue Growth
+9.20%
P/S Ratio
1.84
Revenue / Employee
227.09K
Employees
4,193
Market Cap
1.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 952.17M | 80.21M | 9.20% |
| Dec 31, 2024 | 871.96M | 108.97M | 14.28% |
| Dec 31, 2023 | 762.99M | 79.11M | 11.57% |
| Dec 31, 2022 | 683.88M | 110.07M | 19.18% |
| Dec 31, 2021 | 573.81M | 17.84M | 3.21% |
| Dec 31, 2020 | 555.97M | 21.28M | 3.98% |
| Dec 31, 2019 | 534.70M | 63.02M | 13.36% |
| Dec 31, 2018 | 471.68M | 38.15M | 8.80% |
| Dec 31, 2017 | 433.53M | 11.69M | 2.77% |
| Dec 31, 2016 | 421.84M | -5.72M | -1.34% |
| Dec 31, 2015 | 427.56M | -19.50M | -4.36% |
| Dec 31, 2014 | 447.06M | 104.35M | 30.45% |
| Dec 31, 2013 | 342.71M | 5.21M | 1.54% |
| Dec 31, 2012 | 337.50M | -154.83M | -31.45% |
| Dec 31, 2011 | 492.33M | 68.27M | 16.10% |
| Dec 31, 2010 | 424.06M | 32.74M | 8.37% |
| Dec 31, 2009 | 391.32M | 36.81M | 10.38% |
| Dec 31, 2008 | 354.51M | 50.14M | 16.47% |
| Dec 31, 2007 | 304.37M | 27.40M | 9.89% |
| Dec 31, 2006 | 276.97M | -6.28M | -2.22% |
| Dec 31, 2005 | 283.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| argenx SE | 4.11B |
| Ion Beam Applications | 620.18M |
| European Medical Solutions | 52.80M |
| Nyxoah | 15.33M |
| Hyloris Pharmaceuticals | 7.94M |
| Onward Medical | 5.41M |
| Sequana Medical NV | 105.50K |
Fagron NV News
- 2 months ago - Fagron NV: Fagron shareholders approve all proposed resolutions at the General Meetings - Finanz Nachrichten
- 2 months ago - Fagron shareholders approve all proposed resolutions at the General Meetings - GlobeNewsWire
- 3 months ago - Pete Pharma and Fagron Enter Strategic Distribution Partnership to Expand Access to Pharmaceutical 3D Printing Across North America - Business Wire
- 3 months ago - Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 - GlobeNewsWire
- 3 months ago - Fagron NV Earnings Call Transcript: Q1 2026 - Transcripts
- 3 months ago - Fagron NV Earnings release: Q1 2026 - Filings
- 3 months ago - Fagron NV Slides: Q1 2026 - Filings
- 3 months ago - Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth - GlobeNewsWire